iron sucrose

Iron sucrose is an intravenous iron replacement product consisting of a polynuclear iron(III)-hydroxide core surrounded by a large number of non-covalently bound sucrose molecules. It is primarily indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD), including those who are non-dialysis dependent or dialysis-dependent. The complex is designed to release iron in a controlled manner to iron-binding proteins such as transferrin and ferritin, which then facilitate the production of hemoglobin and the replenishment of iron stores. Beyond CKD, iron sucrose is widely utilized in clinical settings for patients with inflammatory bowel disease (IBD), post-bariatric surgery anemia, and pediatric iron deficiency where oral iron therapy is ineffective or poorly tolerated. Recent developments include the FDA approval of generic versions, such as the one developed by Sandoz and RAFARM in 2025.

Brand names

VenoferFeriv

Other names

iron(III)-hydroxide sucrose complexsaccharated ferric oxideiron sucrose injectionISiron (III)-hydroxy sucrose